Delhi HC seeks response on Natco's patent challenge plea
- Source
- The Economic Times - Industry
- Source link
- https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/delhi-high-court-to-hear-natco-pharmas-patent-challenge-against-novartis-and-astex-for-breast-cancer-drug-ribociclib/articleshow/132966683.cms
- Published
- 2026-08-05 19:19:51
- Discovered by ProcIntel
- 2026-08-05 21:10:34
- Category
- Procurement & Supply Chain News
- Geography
- India
- Organisations
- —
- Review status
- Pending
- Record type
- REAL
Summary
The Delhi High Court is reviewing Natco Pharma's challenge to a breast cancer drug patent. Natco alleges Novartis and Astex secured two patents for the same invention. This action, Natco claims, unlawfully extends patent protection for the Ribociclib molecule. The court will first determine the petition's maintainability after legal arguments. The case has been scheduled for further hearing on September 16.
Procurement Relevance Gate
FAIL
— score 7.0/100 — evaluated 2026-08-05 21:10:34
Only geographic exposure matched — no substantive content indicator, so this cannot pass alone.
- geographic_exposure (weight 8) — matched on "1 linked geography"
Initial Signal Assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically-computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Not Assessed — this Signal did not pass the Procurement Relevance Gate, or is fictional/excluded test data.